AstraZeneca to invest USD 1bn in important innovation — details
Share
The Swedish-British pharmaceutical company AstraZeneca will acquire the biotechnology company EsoBiotec. The agreement may be worth up to USD one billion.
The announcement was made on the official website of AstraZeneca.
Details of the agreement
As noted, EsoBiotec has created the unique technology that allows genetic modification of immune cells directly in the patient's body (in vivo). The company's successes have not gone unnoticed by AstraZeneca, whose scientists are developing cell therapy, especially in the field of cancer treatment. The company not only invests in its own developments but also acquires promising technologies.
The EsoBiotec acquisition will enhance the company's prospects for creating revolutionary cell therapy methods that take minutes to develop. As explained by AstraZeneca, this approach allows cell therapy to be administered via a simple intravenous injection without depleting the patient's immune system.
According to preliminary information, AstraZeneca will take control of 100% of EsoBiotec's shares after the agreement.
As a reminder, gold is once again in the focus of investors' attention. This is due to the instability of the global financial market and, as a result, the search for reliable assets.
We also wrote about AI's role in the rapid rise in the price of fintech startup Stripe.
